Stephen Mayo Sells 7,239 Shares of Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the sale, the director directly owned 1,765 shares in the company, valued at $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Sarepta Therapeutics Stock Down 3.8%

SRPT stock traded down $0.64 during mid-day trading on Friday, hitting $16.40. 2,288,886 shares of the company were exchanged, compared to its average volume of 2,297,338. The firm has a fifty day simple moving average of $19.43 and a 200 day simple moving average of $19.98. The company has a market capitalization of $1.72 billion, a PE ratio of -1.94, a price-to-earnings-growth ratio of 0.25 and a beta of 0.42. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $103.32. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The company had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The business’s revenue for the quarter was down 32.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.90 EPS. On average, research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on SRPT. Weiss Ratings reiterated a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, March 2nd. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a research note on Tuesday, March 3rd. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Wells Fargo & Company lowered their target price on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $32.15.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Kestra Advisory Services LLC acquired a new position in Sarepta Therapeutics during the 4th quarter valued at approximately $25,000. iSAM Funds UK Ltd acquired a new stake in Sarepta Therapeutics in the third quarter worth $25,000. Ancora Advisors LLC lifted its stake in Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares during the last quarter. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics in the third quarter valued at $33,000. Finally, Allworth Financial LP boosted its holdings in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.